Eli Lilly and Co (LLY)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$748.20
Buy
$751.00
$25.60 (+3.50%)
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
Prices updated at 17 May 2025, 00:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
19,974m | 21,493m | 22,320m | 24,540m | 28,318m | 28,541m | 34,124m | 45,043m | |
15,526m | 16,812m | 17,598m | 19,057m | 21,006m | 21,912m | 27,042m | 36,624m | |
4,250m | 6,026m | 5,999m | 7,211m | 7,933m | 8,653m | 10,787m | 17,502m | |
21.28 | 28.04 | 26.88 | 29.38 | 28.01 | 30.32 | 31.61 | 38.86 | |
-204m | 3,232m | 8,318m | 6,194m | 5,582m | 6,245m | 5,240m | 10,590m | |
4,097m | 5,532m | 6,899m | 8,913m | 8,043m | 8,661m | 8,568m | 15,228m | |
Sales, General and administrative | 6,180m | 5,735m | 6,004m | 5,869m | 6,142m | 6,068m | 6,941m | 8,132m |
Interest expenses | 225m | 243m | 401m | 360m | 340m | 332m | 486m | 781m |
Provision for income taxes | 2,391m | 530m | 628m | 1,036m | 574m | 562m | 1,314m | 2,090m |
Operating expenses | 11,276m | 10,786m | 11,599m | 11,846m | 13,073m | 13,258m | 16,255m | 19,123m |
Income before taxes | 2,305m | 3,680m | 5,266m | 7,230m | 6,156m | 6,806m | 6,555m | 12,680m |
Net income available to common shareholders | -204m | 3,232m | 8,318m | 6,194m | 5,582m | 6,245m | 5,240m | 10,590m |
-0.19 | 3.14 | 8.93 | 6.82 | 6.15 | 6.93 | 5.82 | 11.76 | |
Net interest income | -59m | -83m | -320m | -327m | -314m | -269m | -312m | -605m |
Advertising and promotion | - | - | - | - | - | - | - | - |
Net investment income, net | - | - | - | - | - | - | - | - |
Realised capital gains (losses), net | - | - | - | - | - | - | - | - |
Total benefits, claims and expenses | - | - | - | - | - | - | - | - |
Earnings per share (diluted) | -0.19 | 3.13 | 8.89 | 6.79 | 6.12 | 6.9 | 5.8 | 11.71 |
Free cash flow per share | 3.536 | 2.825 | 2.7761 | 5.6003 | 5.0648 | 5.8809 | -0.1825 | -2.5162 |
Book value/share | 13.5365 | 12.371 | 3.5325 | 5.0459 | 8.134 | 10.5981 | 12.4757 | 15.8656 |
Debt equity ratio | 0.857516 | 0.935668 | 5.30051 | 2.940052 | 1.709105 | 1.383829 | 1.700796 | 2.010069 |
Balance sheet
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
Current assets | 19,202m | 20,550m | 13,710m | 17,462m | 18,452m | 18,035m | 25,727m | 32,740m |
Current liabilities | 14,536m | 11,888m | 11,775m | 12,482m | 15,053m | 17,138m | 27,293m | 28,377m |
Total capital | 21,533m | 21,468m | 16,425m | 22,228m | 24,326m | 25,387m | 29,093m | 42,719m |
Total debt | 13,647m | 12,771m | 15,804m | 16,595m | 16,885m | 16,239m | 25,225m | 33,644m |
Total equity | 11,592m | 9,829m | 2,607m | 5,642m | 8,979m | 10,650m | 10,772m | 14,192m |
Total non current liabilities | - | - | - | - | - | - | - | - |
Loans | 9,941m | 11,640m | 13,818m | 16,587m | 15,346m | 14,738m | 18,321m | 28,527m |
Total assets | 44,981m | 43,908m | 39,286m | 46,633m | 48,806m | 49,490m | 64,006m | 78,715m |
Total liabilities | - | - | - | - | - | - | - | - |
Cash and cash equivalents | 6,536m | 7,998m | 2,338m | 3,657m | 3,819m | 2,067m | 2,819m | 3,268m |
Common stock | 1,100m | 1,057m | 958m | 957m | 954m | 950m | 899m | 898m |
Cash flow
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4,582m | 6,536m | 7,998m | 2,338m | 3,657m | 3,819m | 2,067m | 2,819m |
Cash dividends paid | -2,192m | -2,312m | -2,410m | -2,687m | -3,087m | -3,536m | -4,069m | -4,680m |
3,452m | 2,506m | 3,483m | 4,471m | 5,388m | 4,600m | -3,152m | 414m | |
Investments (gains) losses | -3,784m | 1,906m | -8,083m | -2,259m | -2,762m | -3,262m | -7,153m | -9,301m |
6,536m | 7,998m | 2,338m | 3,657m | 3,819m | 2,067m | 2,819m | 3,268m | |
Net income | - | - | - | - | - | - | - | - |
5,616m | 5,525m | 4,837m | 6,500m | 7,261m | 7,084m | 4,240m | 8,818m | |
-2,164m | -3,018m | -1,353m | -2,029m | -1,873m | -2,484m | -7,392m | -8,404m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.